Clinical Trial Update: A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. [Phase 1]

View source ↗

Summary

Phase Ib/Phase 1 trial evaluating the safety and preliminary efficacy of the IL-6 receptor antibody sarilumab in combination with the anti-PD-1 antibody cemipli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Sarilumab (sarilumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING